Summary of Study ST003205

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001998. The data can be accessed directly via it's Project DOI: 10.21228/M8G143 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003205
Study TitleMetabolic profile evolution in relapsed/refractory B-NHL patients treated with CD19.CAR-T cell therapy and implications in clinical outcome
Study TypeNMR Metabolomic
Study SummaryPlasma metabolomics analysis was performed on 44 patients with relapsed/refractory B-cell non Hodgkin lymphoma (r/r/B-NHL) infused with approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and at day +1, +7, and +30 after CAR-T cell infusion. At the PLD time point, a metabolic profile characterized by high lipoproteins and lactate and low glucose contributed to poor outcome prediction in association with high lactate dehydrogenase levels. At day+1, higher plasma levels of lipid metabolism products and lower glucose and glycoproteins levels were observed in tisa-cel- compared to axi-cel-treated patients. At day+30, a higher content of lactate, as well as phenylalanine/tryptophan amino acids which represent the precursors of the key players of myeloid derived suppressor cells were found in patients who relapsed over time compared to patients who maintained complete remission until 1-year. Our data show complex metabolomic changes that track the evolution of the disease and drug activity in the first 30 days of CAR-T cell therapy. Notably, specific metabolic signatures at PLD and day+30, together with a day+30 metabolic profile related to myeloid immunosuppression, are associated with poor outcome.
Institute
UNIVERSITY OF SALENTO
DepartmentD.i.S.T.e.B.A.
LaboratoryGeneral and Inorganic Chemistry
Last NameFANIZZI
First NameFRANCESCO PAOLO
AddressProv.Le Lecce-Monteroni - Centro Ecotekne
Emailfp.fanizzi@unisalento.it
Phone++39-0832-299265
Submit Date2024-05-02
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2024-06-07
Release Version1
FRANCESCO PAOLO FANIZZI FRANCESCO PAOLO FANIZZI
https://dx.doi.org/10.21228/M8G143
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


NMR:

NMR ID:NM000282
Analysis ID:AN005257
Instrument Name:Bruker Avance III NMR
Instrument Type:FT-NMR
NMR Experiment Type:1D-1H
Spectrometer Frequency:600.13 MHz
  logo